DepYmed
Cambridge, United States· Est.
DepYmed is developing potent inhibitors of the enzyme PTP1B which can be applied as potential therapeutic agents for multiple diseases including Rett Syndrome, Wilson Disease and cancer.
Private Company
Total funding raised: $40M
About
DepYmed is developing potent inhibitors of the enzyme PTP1B which can be applied as potential therapeutic agents for multiple diseases including Rett Syndrome, Wilson Disease and cancer.
Small Molecules
Funding History
2Total raised:$40M
Series A$28M
Seed$12M